Insmed

Respiratory and Pulmonary

Insmed

USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with high unmet need battling orphan lung diseases.

USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with high unmet need battling orphan lung diseases.

Its lead product candidate, Arikace (liposomal amikacin for inhalation), is designed to treat rare lung infections in patients who have limited alternatives for treatment.

Arikace is a differentiated, inhaled antibiotic engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the efficacy, safety and convenience of treatment for patients.

Insmed is also continuing late-stage clinical trials for two initial primary target orphan indications for this product: lung infections caused by Pseudomonas in CF patients and lung infections caused by NTM.

Results from both clinical trials are expected in 2013. The company's sole development focus is to obtain regulatory approval for Arikace and to prepare for its commercialization in the USA, Canada and Europe.


Latest Articles

Who's Who

Back to top